학술논문

529: A phase 1b, randomized, double-blind, placebo-controlled, dose-escalation trial of CB-280, an arginase inhibitor, in patients with cystic fibrosis
Document Type
Abstract
Source
In Journal of Cystic Fibrosis November 2021 20 Supplement 2:S250-S250
Subject
Language
ISSN
1569-1993